期刊文献+

圣·约翰草提取物治疗抑郁症临床观察 被引量:1

A study of st.Johnswort extract in treatment of depression
暂未订购
导出
摘要 目的评价圣.约翰草提取物治疗抑郁症的临床疗效和安全性。方法78例抑郁症患者随机分为2组,分别给予圣.约翰草提取物(路优泰)和盐酸阿米替林治疗,疗程8周。采用汉密顿抑郁量表(HAMD),汉密顿焦虑量表(HAMA),临床总体评定量表(CGI)评定临床疗效,不良反应评价用副反应量表(TESS)、实验室检查及体检。结果经8周治疗,圣.约翰草提取物组有效率为85.37%,阿米替林组为89.19%,两组比较差异无统计学意义(P>0.05)。圣.约翰草提取物抗焦虑症状的疗效明显优于阿米替林(P<0.01),不良反应轻微。结论圣.约翰草提取物是一种安全、有效、具有较好抗焦虑作用的抗抑郁剂。 Objective To evaluate the efficacy and safety of st. Johnswort extract in the treatment of depression. Methods Seventyeight patients with depression were randomly divided into st. Johnswort extract group and amitriptyline group and treated with corresponding drags for 8 weeks. Hawihon rating scales for depression and anxiety, and clinical global impression scale were used to evaluate the efficacy. Safety was evaluated using TESS, laboratory test results and physical examination. Results After 8 weeks' treatment, the response rates in st. Johnswort extract group and amitriptyline group were 85.37% and 89.19%, respectively. There were no significant differences between the two groups ( P 〉 0.05). On the other hand, st. Johnswort extract showed higher efficacy against anxiety symptoms than amitriptytine ( P 〈 0.01). The adverse effects of st. Johnswort extract were mild. Conclusion st. Johnswort extract is an effective and safe antidepressant with satisfactory effect on anxiety, symptoms.
出处 《武警医学》 CAS 2006年第6期412-415,共4页 Medical Journal of the Chinese People's Armed Police Force
关键词 圣·约翰草提取物 阿米替林 抑郁症 st. Johnswort extract Amitriptytine Depression
  • 相关文献

参考文献10

  • 1沈渔沌.精神病学.4版.北京:人民卫生出版社,2003.428
  • 2Muller WE,Sing M,Wonnemann U et al.Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract.Pharmacopsychiatry,1998,31 (1):16
  • 3Harrer G,Hubner WD,Podzuweit H.Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline:A multicenter double-blind study.Journal of Geriaric Psychiatry and Neurology,1994,7(1):24
  • 4Laakmann G,Schule C,Baghai T et al.John's wort in mild to moderate depression:The relevance of hyperforin for the clinical efficacy.Pharmacopsychiatry,1998,31(1):54
  • 5De Smet PAGM,Nolen WA.St John's wort as an antidepressant.British Medical Journal,1996,313(2):241
  • 6Harrer G,Sommer H.Treatment of mild/morderate depressions with Hypericum.Therapiewoche,1994,1 (1):3
  • 7Helmut Woelk for the Remotiv/Imipramin study group.Comparison of St.John's wort and imipramine for treating depression:Randomized controlled trial.BMJ,2000,321 (4):536
  • 8张迎黎,张建宏,梁炜,张朝辉,李战文.文拉法辛缓释剂和帕罗西汀治疗抑郁症的对照研究[J].上海精神医学,2003,15(6):341-343. 被引量:18
  • 9Hippius H.St John's Wort (hypericum perforatum)-a herbal antidepressant.Curr Med Res Opin,1998,14(3):171
  • 10ErnstE,RandJI,Barnes J et al.Adverse effects profile of the herbal antideprssant St.John's wort.Eru J Clin Pharmacol,1998,54(8):589

二级参考文献12

  • 1[2]Judge R, Once-daily venlafaxine extended release (XR) vs. fluoxetine for the treatment of depression. J Clin Psychiatry,2001,62( 11 ):888 ~ 893
  • 2[3]Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained of on response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther,2002, 24(7): 1194~1200
  • 3[4]Rusolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reupatake inhibitors. Acta Psychiatr Scand Suppl, 2002, (415) : 24 ~30
  • 4[6]Wellingon K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs, 2001, 15 (8) : 643 ~669
  • 5[7]Silverstone PH, Entsuah R, Hackett D. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine. Int Clin Psychopharmacol, 2002, 17(6) : 273 ~280
  • 6[8]Momtgomery SA, Mahe V, Hardiquet V, et al. Effectiveness of venlafaxine, extended release formulation, in the short-term and longterm treatment of generalized anxiety disorder: results of a survival analysis. J Clin Psychopharmacol, 2002, 22(6) : 561 ~567
  • 7[9]Ables AZ, Baughman OL. Antidepressants: update on new agents and indications. Am Fam Physician, 2003, 67 (3) : 547 ~ 554
  • 8[10]Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry, 2003, 160 (7) : 1252~1262
  • 9[11]Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disord, 2003, 5(2) : 85~97
  • 10[12]Grunze H, Schlosser S, Walden J. New perspectives in the acute treatment of bipolar depression. world J Biol Psychiatry,2000,1 ( 3 ):129 ~ 136

共引文献17

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部